Nuvalent
NUVLNuvalent leverages deep expertise in chemistry and structure-based drug discovery to create precisely targeted therapies that address the dual challenges of kinase resistance and selectivity in oncology. The company's lead programs include zidesamtinib (NVL-520) for ROS1+ NSCLC with PDUFA target action in 2H 2026, and neladalkib (NVL-655) for ALK+ NSCLC currently in Phase 3 trials. With a robust pipeline targeting validated kinase targets and a strong commercial organization, Nuvalent is positioned to deliver durable responses for cancer patients with limited treatment options.
NUVL · Stock Price
Historical price data
AI Company Overview
Nuvalent leverages deep expertise in chemistry and structure-based drug discovery to create precisely targeted therapies that address the dual challenges of kinase resistance and selectivity in oncology. The company's lead programs include zidesamtinib (NVL-520) for ROS1+ NSCLC with PDUFA target action in 2H 2026, and neladalkib (NVL-655) for ALK+ NSCLC currently in Phase 3 trials. With a robust pipeline targeting validated kinase targets and a strong commercial organization, Nuvalent is positioned to deliver durable responses for cancer patients with limited treatment options.
Technology Platform
Structure-based drug discovery platform focused on designing brain-penetrant, selective kinase inhibitors that overcome resistance mutations while minimizing off-target effects in oncology applications.
Pipeline
6| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Neladalkib (NVL-655) + Alectinib | Non-small Cell Lung Cancer | Phase 3 | |
| Zidesamtinib (NVL-520) | Locally Advanced Solid Tumor | Phase 1/2 | |
| Neladalkib (NVL-655) | Locally Advanced Solid Tumor | Phase 1/2 | |
| NVL-330 | Locally Advanced Solid Tumor | Phase 1 | |
| NVL-520 | Non Small Cell Lung Cancer | Pre-clinical |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Operates in competitive precision oncology space against established players in kinase inhibition. Differentiated by brain-penetrant design, selectivity profiles, and focus on overcoming resistance mutations in validated targets like ROS1, ALK, and HER2.